top of page
Search
Illustrative image of surgical suture manufacturing and financial performance

Centenial Surgical Suture FY2026: Revenue Holds Steady Amid Annual Loss

Oct 19
1 min read

October 19, 2026 — A review of the FY2025–26 annual financial disclosures of Centenial Surgical Suture Limited (BSE: 531380) highlights the operating performance of a publicly listed Indian surgical suture manufacturer. This is a review of an earlier annual report, not a newly issued October earnings release.

For the fiscal year ended March 31, 2026, the company recorded annual revenue of approximately ₹538.4 million, compared with ₹535.2 million in the previous year, an increase of approximately 0.6%. The company reported a net loss of approximately ₹22.05 million.

Centenial manufactures and markets absorbable and non-absorbable surgical sutures, including products for cardiovascular applications and atraumatic needle combinations.

The company's public filings provide a view into the financial performance of a specialist suture producer. These consolidated results do not establish sales or margins for individual suture types.

Sources: Centenial Surgical Suture corporate annual reports, https://centenialindia.com/corporate/ ; financial data reference: https://stockanalysis.com/quote/bom/531380/revenue/

Image: original illustrative rendering of surgical sutures and financial performance; not a photograph of any named company's products.

 
 
 

Comments


©2022 by MATRIXLabs Medical Inc. All Rights Reserved.

bottom of page